The stock of Lantheus Holdings Inc (NASDAQ:LNTH) is a huge mover today! About 1.65 million shares traded hands or 235.50% up from the average. Lantheus Holdings Inc (NASDAQ:LNTH) has risen 445.21% since April 14, 2016 and is uptrending. It has outperformed by 440.53% the S&P500.
The move comes after 6 months negative chart setup for the $330.28 million company. It was reported on Nov, 16 by Barchart.com. We have $8.19 PT which if reached, will make NASDAQ:LNTH worth $36.33 million less.
Lantheus Holdings Inc (NASDAQ:LNTH) Ratings Coverage
Out of 5 analysts covering Lantheus Holdings (NASDAQ:LNTH), 2 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 40% are positive. Lantheus Holdings has been the topic of 9 analyst reports since August 31, 2015 according to StockzIntelligence Inc. Robert W. Baird downgraded the shares of LNTH in a report on Monday, August 31 to “Neutral” rating. The stock of Lantheus Holdings Inc (NASDAQ:LNTH) has “Buy” rating given on Monday, August 29 by Jefferies. The rating was downgraded by Credit Suisse on Friday, December 11 to “Neutral”. As per Wednesday, September 30, the company rating was downgraded by Wells Fargo. Credit Suisse initiated Lantheus Holdings Inc (NASDAQ:LNTH) on Friday, September 23 with “Neutral” rating. As per Wednesday, February 24, the company rating was maintained by RBC Capital Markets.
According to Zacks Investment Research, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States.”
More recent Lantheus Holdings Inc (NASDAQ:LNTH) news were published by: Businesswire.com which released: “Lantheus Holdings, Inc. Announces Upsize of Public Offering to 3500000 Shares …” on November 16, 2016. Also Fool.com published the news titled: “Why Lantheus Holdings Inc. Sold Lower Friday” on September 09, 2016. Businesswire.com‘s news article titled: “Lantheus Holdings, Inc. Announces Public Offering of 5200000 Shares of Common …” with publication date: September 08, 2016 was also an interesting one.
LNTH Company Profile
Lantheus Holdings, Inc., incorporated on November 30, 2007, develops, makes and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company’s contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.